Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics.
NKURUNUNGI, G; ZIRIMENYA, L; NATUKUNDA, A; Nassuuna, J; Oduru, G; Ninsiima, C; Zziwa, C; Akello, F; Kizindo, R; Akello, M; KALEEBU, P; WAJJA, A; Luzze, H; COSE, S; WEBB, E; ELLIOTT, AM; POPVAC trial team,;
2021
BMJ open, (2021).11 2 10.1136/bmjopen-2020-040425.
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled tri...
Leach, AJ; MULHOLLAND, EK; Santosham, M; Torzillo, PJ; McIntyre, P; Smith-Vaughan, H; Wilson, N; Arrowsmith, B; Beissbarth, J; Chatfield, MD; Oguoma, VM; Licciardi, P; Skull, S; Andrews, R; Carapetis, J; McDonnell, J; Krause, V; Morris, PS;
2021
Vaccine: X, (2021).7, 10.1016/j.jvacx.2021.100086.
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
Wouters, OJ; Shadlen, KC; Salcher-Konrad, M; Pollard, AJ; LARSON, HJ; Teerawattananon, Y; JIT, M;
2021
Lancet (London, England), (2021).397 10278 10.1016/S0140-6736(21)00306-8.
Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?.
DOCKRELL, HM; BUTKEVICIUTE, E;
2021
Vaccine, (2021).40 11 10.1016/j.vaccine.2021.01.068.
Antibody Responses to Two Recombinant Treponemal Antigens (rp17 and TmpA) before and after Azithromycin Treatment for Yaws in Ghana and Papua New Guinea.
Parameswaran, N; Mitjà, O; BOTTOMLEY, C; Kwakye, C; Houinei, W; Pillay, A; Danavall, D; Chi, K-H; Ballard, RC; Solomon, AW; Chen, CY; Bieb, SV; Adu-Sarkodie, Y; MABEY, DC W; Asiedu, K; MARKS, M; Martin, DL;
2021
Journal of clinical microbiology, (2021).59 5 10.1128/JCM.02509-20.
Who should be prioritized for COVID-19 vaccination in China? A descriptive study.
Yang, J; Zheng, W; Shi, H; Yan, X; Dong, K; You, Q; Zhong, G; Gong, H; Chen, Z; JIT, M; Viboud, C; Ajelli, M; Yu, H;
2021
BMC medicine, (2021).19 1 10.1186/s12916-021-01923-8.
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
ISHOLA, D; MANNO, D; AFOLABI, MO; Keshinro, B; Bockstal, V; Rogers, B; Owusu-Kyei, K; Serry-Bangura, A; Swaray, I; Lowe, B; Kowuor, D; BAIDEN, F; Mooney, T; Smout, E; Köhn, B; Otieno, GT; Jusu, M; Foster, J; Samai, M; Deen, GF; LARSON, H; LEES, S; Goldstein, N; Gallagher, KE; Gaddah, A; ... EBL3001 study group,
2021
Lancet Infectious Diseases, (2021).22 1 10.1016/S1473-3099(21)00125-0.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
AFOLABI, MO; ISHOLA, D; MANNO, D; Keshinro, B; Bockstal, V; Rogers, B; Owusu-Kyei, K; Serry-Bangura, A; Swaray, I; Lowe, B; Kowuor, D; Baiden, F; Mooney, T; Smout, E; Köhn, B; Otieno, GT; Jusu, M; Foster, J; Samai, M; Deen, GF; LARSON, H; LEES, S; Goldstein, N; GALLAGHER, KE; Gaddah, A; ... EBL3001 study group,
2021
Lancet Infectious Diseases, (2021).22 1 10.1016/S1473-3099(21)00128-6.
Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis.
PREM, K; Choi, YH; Bénard, É; Burger, E; Hadley, L; Laprise, J-F; Regan, MC; Drolet, M; Sy, S; Abbas, K; Portnoy, A; Kim, J; Brisson, M; JIT, M;
2021
medRxiv (2021). 10.1101/2021.02.08.21251186.
Methods for Social Media Monitoring Related to Vaccination: Systematic Scoping Review.
Karafillakis, E; Martin, S; Simas, C; Olsson, K; Takacs, J; DADA, S; LARSON, HJ;
2021
JMIR public health and surveillance, (2021).7 2 10.2196/17149.